Pharma News

The United States Food and Drug Administration (FDA) has granted Fast Track designation to Trevena's oliceridine (TRV130) for the management of moderate-to-severe acute pain. Oliceridine is being developed as a potential replacement for currently approved intravenous opioid analgesics.

Researchers have developed a new vaccine strategy that reduces the risk of flu infections in cancer patients at highest risk for influenza.

Reduced antibiotic prescribing by doctors is associated with lower patient satisfaction, a Britain-based survey shows.

Consumption of tea, particularly black and green, greatly reduces the risk of cancer in human beings due to the presence of anti-oxidant agents, according to a researcher with a US university.

[adsense:336x280:8701650588]

Reduced cell density in certain parts of the hippocampus - a brain region that processes and stores memories - may be linked to deficits in short- and long-term memory in people with epilepsy, particularly those with seizures that affect the temporal lobe, new research has found.

Older adults with chronic lymphocytic leukemia, a type of slow-growing blood cancer, may have a better alternative to toxic chemotherapy as their first treatment, results of a phase three clinical trial show.

With diabetes affecting a large section of India's population, the chronic health condition can adversely affect the country's economic growth, experts have warned.

Scientists at University College London (UCL) have found the recipe for painlessness in a study that used genetically modified mice to show a channel responsible for allowing pain signals to pass along nerve cell membranes is vital to feel agony.

Sun Pharmaceutical Industries Ltd. has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Gleevec®, Imatinib Mesylate tablets 100mg and 400mg. Gleevec® is the registered trademark of Novartis Pharmaceuticals Corporation.

Cipla Ltd, a global pharmaceutical company announced that it has launched a novel “5 in 1” anti-ageing skin care product Cutisera developed by Stempeutics. Cutisera has been developed using bio-active factors derived from human adult stem cells to enhance the rejuvenation of ageing skin.